Abstract:Objective: To explore the feasibility and accuracy of 0-1 h high sensitivity cardiac troponin I (hs-cTnI) concentration and its changes in judging non-ST segment elevation myocardial infarction (NSTEMI), and to investigate the feasibility of a simplified process. Methods: Patients with acute chest pain and suspected NSTEMI who were admitted to the emergency department of Fuwai Hospital, the First Affiliated Hospital of Sun Yat-sen University and Nanjing First Hospital from January 2017 to September 2020 were selected. Hs-cTnI test was carried out for the selected patients at the time of visit (0 h) and 1 h after visit. According to the 0-1 h hs-cTnI diagnostic process and threshold standard recommended by European Society of Cardiology (ESC) guidelines in 2015, the laboratory adjudication was determined. Cardiologists who did not participate in the project design and did not know the results of hs-cTnI test performed the clinical judgment according to the routine diagnosis and treatment process of emergency department. Taking clinical judgment as the gold standard, the diagnostic efficacy of 0-1 h hs-cTnI concentration and its change recommended by the guidelines for judging NSTEMI in Chinese population was analyzed. The guide process was simplified. Under the condition of not considering the time of chest pain, the guideline threshold was used for test and judgement, and the diagnostic efficacy of the simplified process was evaluated. Results: A total of 1 534 patients were enrolled in the study, aged (62±12) years and 952 (62.1%) patients were male. Among them, 402 patients (26.2%) were clinically diagnosed as NSTEMI and 1 132 patients (73.8%) were diagnosed as non-NSTEMI. According to the diagnosis and determination process recommended by the guidelines, NSTEMI was excluded in 672 patients (42.8%), and 464 patients (30.2%) were diagnosed as NSTEMI. The consistency rate with clinical determination reached 92.4% (1 050/1 136), the sensitivity of excluding diagnosis was 99.5% (95%CI: 98.0%-99.9%), the negative predictive value was 99.7% (95%CI: 98.8%-99.9%), and the negative likelihood ratio was 0.008 (95%CI: 0.002-0.335). The diagnostic specificity was 92.6% (95%CI: 90.9%-94.0%), the positive predictive value was 81.9% (95%CI: 78.0%-85.2%), and the positive likelihood ratio was 12.739 (95%CI: 10.356-15.670). According to the simplified process, NSTEMI was excluded in 675 patients (44.0%), and 463 patients (30.2%) were diagnosed as NSTEMI. The consistency rate with clinical judgment was 92.4% (1 051/1 138), the sensitivity of exclusion diagnosis was 99.3% (95%CI: 97.6%-99.8%), the negative predictive value was 99.6% (95%CI: 98.6%-99.9%), and the negative likelihood ratio was 0.012 (95%CI: 0.004-0.389). The diagnostic specificity was 92.6% (95%CI: 90.9%-94.0%), the positive predictive value was 81.9% (95%CI: 78.0%-85.2%), and the positive likelihood ratio was 12.705 (95%CI: 10.328-15.630). There was no significant difference in diagnostic efficacy between the simplified process and the recommended process (all P>0.05). Conclusion: The diagnostic process for judging NSTEMI according to the 0-1 h hs-cTnI concentration and its change criteria recommended by the 2015 ESC guidelines is applicable in the Chinese population and remains highly accurate in judging NSTEMI without considering the duration of chest pain at the time of presentation.

Effect of Combined Testing of Ceramides with High-Sensitive Troponin T on the Detection of Acute Coronary Syndrome in Patients with Chest Pain in China: a Prospective Observational Study

Prognostic Significance of Coronary Artery Calcium Scoring and Single-Photon Emission Computed Tomographic Myocardial Perfusion Imaging on Major Adverse Cardiac Events in Patients at Low Risk for Suspected Coronary Artery Disease.

Association Between Plasma Ceramides and One-Year Mortality in Patients with Acute Coronary Syndrome: Insight from the PEACP Study

Ceramides and metabolic profiles of patients with acute coronary disease: a cross-sectional study

[Efficacy Analysis of High-Sensitivity Troponin I Concentration and Its Changes in the Diagnosis of Acute Myocardial Infarction].

Pregnancy-Associated Plasma Protein A And Copeptin As Markers In The Early Diagnosis Of Acute Coronary Syndrome

Prognostic Value of Highly Sensitive C-Reactive Protein and Plaque Morphology in Coronary Artery Disease in China.

Platelet Carcinoembryonic Antigen Cell Adhesion Molecule 5 (Ceacam5) As A Possible Novel Diagnostic Tool For Evaluation Of Acute Coronary Syndrome

Clinical Impact of Using a More Sensitive Troponin Assay in Patients with Acute Chest Pain.

The relationship between ceramide profile and residual inflammatory risk in patients with coronary artery disease: Insights from an prospective study

Value of biochemical marker detection in risk stratification in patients with acute coronary syndrome]

Application of Enhanced Cardiac Troponin Ⅰ Determination in Clinical Diagnosis of Acute Coronary Syndrome

The Serum Metabolic Biomarkers in Early Diagnosis and Risk Stratification of Acute Coronary Syndrome

Ceramides As Potential New Predictors of the Severity of Acute Coronary Syndrome in Conjunction with SARS-CoV-2 Infection

Plasma ceramides are associated with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction

The Combination of Creatine Kinase-Myocardial Band Isoenzyme and Point-of-care Cardiac Troponin/contemporary Cardiac Troponin for the Early Diagnosis of Acute Myocardial Infarction

Multi-Marker Approach in Patients with Acute Chest Pain in the Emergency Department

Efficacy of Coronary Calcium Score in Predicting Coronary Artery Morphology in Patients With Obstructive Coronary Artery Disease

Clinical Value of Combined Assay of Serumal Matrix Metalloproteinases-9 and C-reactive Protein in Patients with Coronary Artery Disease

Ceramides and pro-inflammatory cytokines for the prediction of acute coronary syndrome: a multi-marker approach

Clinical value of combined detection of serum total sialic acid, sialidase and high sensitivity C-reactive protein in patients with acute myocardial infarction